Lars Vilén
Impact in
- Hematology top 10%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Platelet Disorders and Treatments
- Genetics top 10%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Antiplatelet Therapy and Cardiovascular Diseases 9
- Acute Myocardial Infarction Research 4
-
- Chronic Myeloid Leukemia Treatments 5
- Platelet Disorders and Treatments 2
- Co-authors
- Jack Kutti (13 shared papers)Hans Wadenvik (4 shared papers)Börje Ridell (2 shared papers)Per Lundborg (3 shared papers)Hans Wedel (2 shared papers)Peter Johansson (2 shared papers)Björn Andréasson (2 shared papers)Soodabeh Safai‐Kutti (2 shared papers)
- Journals
- Journal of Internal Medicine (2 papers)Thrombosis and Haemostasis (2 papers)Stem Cells (1 paper)Acta Haematologica (1 paper)British Journal of Haematology (1 paper)
- Partner nations
- SwedenNorwayUnited Kingdom
In The Last Decade
Lars Vilén
18 papers receiving 247 citations
Peers
Comparison fields: 5 of 58
- Hematology 141
- Genetics 131
- Rheumatology 62
- Internal Medicine 15
- Cardiology and Cardiovascular Medicine 58
Countries citing papers authored by Lars Vilén
This map shows the geographic impact of Lars Vilén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Vilén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Vilén more than expected).
Fields of papers citing papers by Lars Vilén
This network shows the impact of papers produced by Lars Vilén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Vilén. The network helps show where Lars Vilén may publish in the future.
Co-authors
The 25 scholars most cited alongside Lars Vilén, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 48 | |
| 2 | 1991 | 37 | |
| 3 | 1978 | 23 | |
| 4 | 2000 | 20 | |
| 5 | 1989 | 17 | |
| 6 | 2002 | 16 | |
| 7 | 1993 | 15 | |
| 8 | 1992 | 15 | |
| 9 | 1985 | 13 | |
| 10 | 1983 | 12 | |
| 11 | 1985 | 11 | |
| 12 | Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group. | 1996 | 9 |
| 13 | 1980 | 9 | |
| 14 | 1985 | 8 | |
| 15 | 2002 | 7 | |
| 16 | 1978 | 6 | |
| 17 | 1979 | 3 | |
| 18 | 1986 | 1 |
About Lars Vilén
Lars Vilén is a scholar working on Cardiology and Cardiovascular Medicine, Hematology, Genetics, Rheumatology and Analytical Chemistry, having authored 18 papers that have together received 270 indexed citations. Recurring topics across this work include Antiplatelet Therapy and Cardiovascular Diseases (9 papers), Chronic Myeloid Leukemia Treatments (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers), Acute Myocardial Infarction Research (4 papers), Analytical Methods in Pharmaceuticals (3 papers), Eosinophilic Disorders and Syndromes (3 papers), Platelet Disorders and Treatments (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Hematology (141 citations), Genetics (131 citations), Rheumatology (62 citations), Internal Medicine (15 citations) and Cardiology and Cardiovascular Medicine (58 citations). Lars Vilén has collaborated with scholars based in Sweden, Norway and United Kingdom. Frequent co-authors include Jack Kutti, Hans Wadenvik, Börje Ridell, Per Lundborg, Hans Wedel, Peter Johansson, Björn Andréasson, Soodabeh Safai‐Kutti, Jan Westin and Jan Carneskog. Their work appears in journals such as Journal of Internal Medicine, Thrombosis and Haemostasis, Stem Cells, Acta Haematologica and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.